Translating Novel Modalities from Concept to Clinic to Strengthen Phage’s Therapeutic Future
- Addressing CMC, stability, and delivery challenges unique to synthetic or proteinbased antimicrobials
- Aligning development pathways with evolving regulatory expectations for nontraditional therapeutics
- Ensuring robust preclinical models and manufacturing scalability to accelerate realworld clinical adoption